| Literature DB >> 32839415 |
Suji Kim1, Won-Jun Jang1, Hyerim Yu1, Jihyun Kim2, Sang-Ki Lee2, Chul-Ho Jeong1, Sooyeun Lee1.
Abstract
Methamphetamine (MA) is a highly addictive central nervous system stimulant. Drug addiction is not a static condition but rather a chronically relapsing disorder. Hair is a valuable and stable specimen for chronic toxicological monitoring as it retains toxicants and metabolites. The primary focus of this study was to discover the metabolic effects encompassing diverse pathological symptoms of MA addiction. Therefore, metabolic alterations were investigated in human hair following heavy MA abuse using both targeted and untargeted mass spectrometry and through integrated network analysis. The statistical analyses (t-test, variable importance on projection score, and receiver-operator characteristic curve) demonstrated that 32 metabolites (in targeted metabolomics) as well as 417 and 224 ion features (in positive and negative ionization modes of untargeted metabolomics, respectively) were critically dysregulated. The network analysis showed that the biosynthesis or metabolism of lipids, such as glycosphingolipids, sphingolipids, glycerophospholipids, and ether lipids, as well as the metabolism of amino acids (glycine, serine and threonine; cysteine and methionine) is affected by heavy MA abuse. These findings reveal crucial metabolic effects caused by MA addiction, with emphasis on the value of human hair as a diagnostic specimen for determining drug addiction, and will aid in identifying robust diagnostic markers and therapeutic targets.Entities:
Keywords: drug addiction; hair; lipid metabolism; metabolomics; methamphetamine; network analysis
Mesh:
Substances:
Year: 2020 PMID: 32839415 PMCID: PMC7503996 DOI: 10.3390/ijms21176041
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Study subjects and hair concentrations of methamphetamine (MA) and amphetamine (AM).
| Subjects | ID | Age (Years) | Concentrations (ng/mg) | ||
|---|---|---|---|---|---|
| MA 1 | AM 2 | ||||
| Drug-free controls | Mean (SD) | C1 | 36 | - | - |
| C2 | 34 | ||||
| C3 | 40 | ||||
| C4 | 40 | ||||
| C5 | 42 | ||||
| C6 | 44 | ||||
| C7 | 48 | ||||
| C8 | 35 | ||||
| C9 | 40 | ||||
| C10 | 41 | ||||
| C11 | 40 | ||||
| C12 | 37 | ||||
| 39.8 (3.9) | |||||
| Heavy MA abusers | M1 | 37 | 65.7 | 4.6 | |
| M2 | 36 | 163.4 | 8.5 | ||
| M3 | 36 | 72.5 | 0.2 | ||
| M4 | 27 | 28.5 | 1.9 | ||
| M5 | 37 | 48.7 | 2.4 | ||
| M6 | 46 | 31.2 | 2.7 | ||
| M7 | 30 | 75.8 | 6.3 | ||
| M8 | 37 | 63.74 | 4.3 | ||
| M9 | 38 | 25.2 | 3.7 | ||
| M10 | 46 | 25.2 | 2.0 | ||
| Mean (SD) | 37.0 (5.9) | 60.0 (41.5) | 3.7 (2.4) | ||
1 Methamphetamine; 2 Amphetamine.
Number of metabolites investigated in human hair.
| Metabolite Group | Total Number of Metabolites | Number of (Semi-) Quantified Metabolites | Number of Significant Changed Metabolites |
|---|---|---|---|
| Acylcarnitines | 40 | 22 | 5 |
| Amino acids and biogenic amines | 42 | 22 | 2 |
| Glycerophospholipids | 90 | 39 | 25 |
| Sphingolipids | 15 | 7 | 3 |
| Monosaccarids | 1 | 0 | 0 |
| Total | 188 | 90 | 35 |
Figure 1Statistical results of targeted metabolomics in hair samples from drug-free controls (n = 12) and heavy MA abusers (n = 10). (a) Principal component analysis (PCA) score plot. Red circle: drug-free controls; green circle: heavy MA abusers. (b) Volcano plot; red circle: metabolites with significance at p < 0.05 and fold change > 1.2 or < −1.2. (c) Partial least squares discriminant analysis (PLS-DA) score plot. Red circle: drug-free controls; green circle: heavy MA abusers. (d) Variable importance on projection (VIP) score plot. Colored box: relative concentration in drug-free controls and heavy MA abusers; (e) Venn diagram integrating results from the t-test, VIP scores, and receiver-operator characteristic (ROC) curves.
Significantly changed metabolites in the hair samples from heavy MA abusers.
| Metabolite Group | Metabolite | Fold Change | |
|---|---|---|---|
| Acylcarnitines | Carnitine | 1.80 | 0.0065 |
| Decadienylcarnitine | 2.51 | 0.0119 | |
| Octadecadienylcarnitine | 2.39 | 0.0224 | |
| Octadecanoylcarnitine | −1.45 | 0.0047 | |
| Valerylcarnitine | −1.92 | 0.0062 | |
| Amino acids and biogenic amines | Arginine | 5.61 | 0.0044 |
| Methionine | −1.56 | 0.0049 | |
| Glycerophospholipids | lysoPC a 1 C160 | 2.14 | 0.0007 |
| lysoPC a C170 | 1.73 | 0.0002 | |
| lysoPC a C181 | 2.74 | 4.0469 × 10−5 | |
| lysoPC a C204 | 1.33 | 0.0478 | |
| PC aa 2 C341 | −1.52 | 0.0092 | |
| PC aa C362 | −1.41 | 0.0185 | |
| PC aa C365 | −2.78 | 7.5669 × 10−5 | |
| PC aa C366 | −2.13 | 0.0010 | |
| PC aa C381 | −1.59 | 0.0382 | |
| PC aa C383 | −1.37 | 0.0091 | |
| PC aa C385 | −2.33 | 0.0002 | |
| PC aa C403 | −2.56 | 0.0043 | |
| PC aa C404 | −2.22 | 0.0061 | |
| PC ae 3 C340 | −1.89 | 0.0033 | |
| PC ae C360 | −1.69 | 0.0015 | |
| PC ae C361 | −1.61 | 0.0054 | |
| PC ae C365 | −3.13 | 0.0001 | |
| PC ae C380 | −1.59 | 0.0020 | |
| PC ae C381 | −2.04 | 0.0026 | |
| PC ae C382 | −2.08 | 0.0035 | |
| PC ae C383 | −2.08 | 0.0078 | |
| PC ae C401 | −2.78 | 0.0005 | |
| PC ae C402 | −2.27 | 0.0071 | |
| PC ae C422 | −2.04 | 0.0150 | |
| PC ae C423 | −1.92 | 0.0284 | |
| Sphingolipids | SM 4 C241 | 2.04 | 0.0184 |
| SM OH C221 | 1.77 | 0.0163 | |
| SM OH C241 | 1.51 | 0.0236 |
1 Lysophosphatidylcholine acyl; 2 Phosphatidylcholine diacyl; 3 Phosphatidylcholine acyl-alkyl; 4 Sphingomyelin, SM.
Figure 2Results of the receiver operating characteristic (ROC) curve analysis of the 37 metabolites from t-test, variable importance on projection scores, and ROC curves in targeted metabolomics and metabolite levels. AUC: area under the ROC curve.
Figure 3Statistical results of untargeted metabolomics by the positive ionization mode of ultra-high-performance liquid chromatography coupled to quadrupole time-of-flight electrospray ionization mass spectrometry (UPLC-QTOF-ESI-MS) in hair samples from drug-free controls (n = 12) and heavy MA abusers (n = 10). (a) Principal component analysis (PCA) score plot. Red circle: drug-free controls; green circle: heavy MA abusers. (b) Volcano plot. Red circle: metabolites with significance at p < 0.05 and fold change > 1.2 or < −1.2: +ND: increased from the value of not detected. (c) Partial least squares discriminant analysis (PLS-DA) score plot. Red circle: drug-free controls; green circle: heavy MA abusers. (d) Variable importance on projection (VIP) score plot. Colored box: relative concentration in drug-free controls and heavy MA abusers; (e) Venn diagram integrating results from the t-test, VIP scores, and receiver-operator characteristic (ROC) curve.
Figure 4Statistical results of untargeted metabolomics using the negative ionization mode of quadrupole time-of-flight electrospray ionization mass spectrometry (UPLC-QTOF-ESI-MS) in hair samples from drug-free controls (n = 12) and heavy MA abusers (n = 10). (a) Principal component analysis (PCA) score plot. Red circle: drug-free controls; green circle: heavy MA abusers. (b) Volcano plot. Red circle: metabolites with significance at p < 0.05 and fold change > 1.2 or < −1.2. (c) Partial least squares discriminant analysis (PLS-DA) score plot. Red circle: drug-free controls; green circle: heavy MA abusers. (d) Variable importance on projection (VIP) score plot. Colored box: relative concentrations in drug-free controls and heavy MA abusers. (e) Venn diagram integrating results from the t-test, VIP scores, and receiver-operator characteristic (ROC) curves.
Metabolites identified in the hair via LC-QTOF-ESI-MS analysis using in-house database.
| Ionization Polarity | tR (min) | ΔtR (min) | Formula | Mass | ΔMass (ppm) | Metabolites | Species | Score | |
|---|---|---|---|---|---|---|---|---|---|
| Positive | 130.0507 | 1.14 | −0.31 | C5H7NO3 | 129.0434 | −6.49 |
| (M + H)+ | 83.5 |
| 132.1022 | 1.32 | 0.03 | C6H13NO2 | 131.0949 | −2.11 |
| (M + H)+ | 99.4 | |
| 139.0523 | 1.42 | 0.00 | C6H6N2O2 | 138.0452 | −16.54 |
| (M + H)+ | 70.6 | |
| 146.0926 | 1.27 | 0.14 | C5H11N3O2 | 145.0852 | −0.41 |
| (M + H)+ | 83.6 | |
| 195.0873 | 14.64 | −0.04 | C8H10N4O2 | 194.0800 | 1.84 |
| (M + H)+ | 99.1 | |
| 302.3051 | 35.96 | 0.01 | C18H39NO2 | 301.2978 | 0.88 | * Sphinganine (−1.8) | (M + H)+ | 99.6 | |
| Negative | 151.0258 | 2.64 | 0.01 | C5H4N4O2 | 152.0330 | 2.63 | Xanthine | (M − H)− | 98.1 |
| 167.0207 | 1.75 | −0.07 | C5H4N4O3 | 168.0280 | 1.87 | * Urate (−2.0) | (M − H)− | 86.6 | |
| 117.0193 | 1.51 | 0.03 | C4H6O4 | 118.0266 | 0.18 |
| (M − H)− | 87.7 | |
| 281.2484 | 39.56 | −0.04 | C18H34O2 | 282.2556 | 0.92 | * Petroselinic acid (−3.3) | (M − H)− | 99.4 | |
| 105.0199 | 0.90 | −0.02 | C3H6O4 | 106.0272 | −5.39 | Glycerate | (M − H)− | 85.5 | |
| 89.0250 | 1.04 | 0.19 | C3H6O3 | 90.0323 | −6.46 | Glyceraldehyde | (M − H)− | 85.4 | |
| 131.0824 | 0.85 | 0.13 | C5H12N2O2 | 132.0896 | 2.13 | (L-)Ornithine | (M − H)− | 85.1 | |
| 174.0882 | 0.85 | 0.09 | C6H13N3O3 | 175.0955 | 0.97 | Citrulline | (M − H)− | 87.1 | |
| 128.0354 | 1.48 | 0.03 | C5H7NO3 | 129.0427 | −0.49 | 5-Oxo-proline | (M − H)− | 87.7 | |
| 121.0294 | 9.68 | 0.14 | C7H6O2 | 122.0367 | 0.84 | * | (M − H)− | 87.8 |
* p < 0.05. Fold changes are parenthesized. Underlined metabolites were additionally confirmed using MS/MS analysis.
Figure 5Altered metabolic pathways identified by PIUMet.
Altered metabolism pathways identified in the hair from heavy MA abusers.
| Module | Metabolism Pathway | Number of Hidden Proteins | FDR 1 | Hidden Protein | |
|---|---|---|---|---|---|
| 1 | Peroxisome | 4 | 9.99 × 10−8 | 1.40 × 10−6 | ACOT8,PEX5,HACL1,PAOX |
| 2 | Glycosphingolipid biosynthesis—lacto and neolacto series | 3 | 2.71 × 10−7 | 1.38 × 10−5 | B3GALT5,B3GNT3,A4GALT |
| 3 | Glycine, serine and threonine metabolism | 4 | 5.44 × 10−9 | 1.09 × 10−7 | SHMT2,SHMT1,GNMT,SARDH |
| 4 | Sphingolipid metabolism | 3 | 1.42 × 10−6 | 3.42 × 10−5 | SMPD3,SMPD2,SMPD4 |
| 5 | Cysteine and methionine metabolism | 3 | 2.48 × 10−6 | 1.74 × 10−5 | BHMT2,MTR,BHMT |
| 6 | Glycerophospholipid metabolism | 4 | 2.69 × 10−8 | 5.38 × 10−7 | LYPLA2,LYPLA1,PLA2G2C,PLA2G15 |
| 7 | Pentose and glucuronate interconversions | 3 | 1.09 × 10−7 | 2.05 × 10−6 | UGT2B4,GUSB,UGT2B7 |
| Drug metabolism—other enzymes | 3 | 1.36 × 10−6 | 8.15 × 10−6 | UGT2B4,GUSB,UGT2B7 | |
| 8 | Ether lipid metabolism | 4 | 2.99 × 10−10 | 4.18 × 10−9 | PLA2G12B,PLA2G7,PAFAH1B3,PAFAH2 |
1 False discovery rate.